MLICM
FMTX

Metropolitan Life Insurance Company (MetLife)’s Forma Therapeutics Holdings, Inc. Common Stock FMTX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio FMTX Stock Details FMTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,208
Closed -$44K – 2393
2022
Q3 		$44K Hold
2,208
– – ﹤0.01% 1544
2022
Q2 		$15.2K Hold
2,208
– – ﹤0.01% 2172
2022
Q1 		$20.5K Sell
2,208
-6,986
-76% -$74.4K ﹤0.01% 2083
2021
Q4 		$131K Hold
9,194
– – ﹤0.01% 2319
2021
Q3 		$213K Hold
9,194
– – ﹤0.01% 2014
2021
Q2 		$229K Buy
9,194
+465
+5% +$12.5K ﹤0.01% 2047
2021
Q1 		$245K Buy
8,729
+3,900
+81% +$141K ﹤0.01% 1874
2020
Q4 		$169K Hold
4,829
– – ﹤0.01% 2045
2020
Q3 		$241K Buy
+4,829
New +$195K ﹤0.01% 1665

Metropolitan Life Insurance Company (MetLife)'s FMTX Position: Q4 2022 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Forma Therapeutics Holdings, Inc. Common Stock (FMTX) in Q4 2022, closing a stake of 2,208 shares — an estimated $44K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in FMTX in Q3 2020 and held it in 9 quarters. The position peaked at $245K in Q1 2021. 0 funds tracked by Wall St. Rank hold FMTX as of Q4 2022.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Forma Therapeutics Holdings, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 2,208 Forma Therapeutics Holdings, Inc. Common Stock shares in Q4 2022, an estimated $44K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Forma Therapeutics Holdings, Inc. Common Stock in Q3 2020 and held it in 9 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Forma Therapeutics Holdings, Inc. Common Stock position peaked at $245K in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Forma Therapeutics Holdings, Inc. Common Stock as of Q4 2022.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2022, filed 15 Feb 2023.